# Antiparkinsonian Drugs

> Antiparkinsonian drugs in MBBS Pharmacology: levodopa-carbidopa, dopamine agonists, MAO-B and COMT inhibitors, amantadine and anticholinergics.

- Canonical URL: https://prepelephant.com/topics/mbbs/pharmacology/antiparkinsonian-drugs
- Exam / course: MBBS · Subject: Pharmacology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Antiparkinsonian Drugs", PrepElephant, https://prepelephant.com/topics/mbbs/pharmacology/antiparkinsonian-drugs

## Direct answer

Since nigrostriatal dopamine cannot cross the blood-brain barrier, Parkinson's pharmacology begins with its precursor: levodopa, always paired with peripheral carbidopa (about 4:1), which blocks extracerebral decarboxylation, cuts the required dose drastically and prevents nausea. Around levodopa orbit the adjuncts — dopamine agonists (pramipexole, ropinirole) for younger patients, MAO-B inhibitors (selegiline, rasagiline) for early disease, entacapone to extend each dose, amantadine for dyskinesia, and anticholinergics only for young, tremor-predominant disease. Disease duration rewrites the agenda: early, smooth dopaminergic cover; late, management of wearing-off, on-off swings, dyskinesia and psychosis — without precipitating either motor collapse or confusion.

## What you must remember

- **Carbidopa's logic:** a peripheral dopa decarboxylase inhibitor that never enters brain; 70-100 mg daily saturates the enzyme, allowing roughly a quarter of the levodopa dose with far less vomiting and orthostasis.
- **Motor complications:** wearing-off (end-of-dose deterioration) answered by dose fractionation, controlled-release or entacapone; on-off swings by agonists or infusion strategies; peak-dose dyskinesia by amantadine or dose smoothing.
- **Agonist hazards:** sudden sleep attacks (a driving warning), impulse-control disorders — gambling, hypersexuality, shopping — ankle oedema; ergot agonists add retroperitoneal and valvular fibrosis.
- **Selegiline:** MAO-B inhibitor with amphetamine metabolites (morning dosing, insomnia); avoid pethidine; rasagiline carries no such metabolite.
- **Amantadine:** NMDA antagonist, the only drug that suppresses levodopa dyskinesia; causes livedo reticularis, ankle oedema, confusion, and needs renal dose adjustment.
- **Anticholinergics:** trihexyphenidyl for young tremor-dominant disease; barred in closed-angle glaucoma and prostatism, and confuse the elderly.
- **Drug-induced parkinsonism:** from metoclopramide, haloperidol, fluphenazine — stop the culprit rather than add treatment.

## Timing therapy across the disease

Early disease buys time: selegiline or rasagiline alone, or an agonist in a patient under 60, delays the levodopa clock while symptoms are mild. When disability interferes with work, levodopa-carbidopa starts low and climbs slowly — the most effective symptomatic drug in neurology, and the one whose complications eventually surface. Five years on, the same patient returns predicting his doses by the clock: wearing-off answered by smaller doses more often plus entacapone; dyskinesia at peak dose by amantadine; distressing hallucinations at night by trimming the evening anticholinergic and agonist first, then adding quetiapine or clozapine — never a typical antipsychotic, which strips dopaminergic cover and paralyse the patient anew.

The reverse trap waits in the medical ward: an elderly woman "slowed down" after starting metoclopramide for gastroparesis has drug-induced parkinsonism. The treatment is withdrawal of the culprit, not a prescription of levodopa.

## Indian prescribing context

Levodopa-carbidopa, trihexyphenidyl and pramipexole are NLEM-listed, making standard Parkinsonian therapy reachable in district hospitals; entacapone and apomorphine remain private-sector drugs, which shapes what Indian examiners call realistic escalation. Two local habits merit comment: brand loyalty to a single carbidopa-levodopa name makes pharmacy-level substitution confusing (know the strength ratios, 100/25 and 50/12.5), and anticholinergics still circulate for vague "tremor" complaints in the elderly, where confusion is the predictable cost. Impulse-control disorder on pramipexole belongs in the history, not just the textbooks — ask Indian patients directly; report dyskinesia and sleep attacks to the PvPI.

## Frequently asked questions

### Why is carbidopa combined with levodopa?

It blocks peripheral dopa decarboxylase without crossing the blood-brain barrier, so more levodopa reaches brain, the effective dose falls about fourfold, and nausea and orthostatic hypotension decline.

### How is levodopa-induced dyskinesia managed?

Reduce or redistribute individual doses, add amantadine, and consider infusion or surgical options; anticholinergics worsen, not help, dyskinesia.

### Which antiparkinsonian class suits young tremor-predominant disease?

Anticholinergics such as trihexyphenidyl, provided closed-angle glaucoma and prostatism are excluded and cognition is intact.

### Which drugs should parkinsonian patients avoid?

Dopamine blockers — metoclopramide, haloperidol, promethazine in high dose — for vomiting or psychosis use domperidone (cautiously) or quetiapine and clozapine.

### What is the selegiline-pethidine interaction?

Life-threatening hyperpyrexia, agitation and rigidity resembling malignant syndrome; pethidine is contraindicated with all MAO inhibitors, selegiline included.